Table of Contents
| << Previous Issue | Feb 2012 (Vol: 2012, Issue: 2) | Next Issue >> |
- Section: Cartoons
-
Injections
- Section: Distribution & Marketing
-
Impax In-Licenses US Commercial Rights to AstraZeneca’s Migraine Drug Zomig®
- Section: Joint Venture
-
Merck & Co. Forms Joint Venture with Supera Farma Laboratorios to Increase its Presence in Brazil
- Section: Licensing
-
Ironwood Pharmaceuticals Expands its Pipeline Beyond Linaclotide with Bionomics Deal
-
Merck KGaA Boosts its Late-Stage Pipeline by Licensing Threshold’s Hypoxia-Targeted Cancer Drug
-
Enanta Pharmaceuticals Partners its Lead HCV NS5A Inhibitor with Novartis
- Section: Mergers & Acquisitions
-
Alexion Gains First Potential Drug for Hypophosphatasia via US$1.08 B Enobia Buyout
-
Amgen Boosts its Oncology Pipeline with US$1.16 B Acquisition of Micromet
-
Watson Strengthens its Presence in Australia and Southeast Asia with Acquisition of Strides Arcolab’s Ascent Pharmahealth
-
Celgene Gains Covalent Drug Pipeline and Platform via Avila Therapeutics Acquisition
-
Valeant Agrees to Buy Eyetech to Strengthen its Ophthalmology Business
-
Biogen Idec Retrieves its Idiopathic Pulmonary Fibrosis Drug via US$562.5 M Stromedix Acquisition
- Section: Research & Development
-
Forma Therapeutics and Janssen Biotech Target Tumour Metabolism with US$700 M Drug Discovery Alliance
-
Forma Therapeutics and Boehringer Ingelheim Partner to Target Oncology-Relevant Protein-Protein Interactions
-
Xenon and Genentech Partner to Develop Pain Therapeutics and Companion Diagnostics
-
Constellation and Genentech Form Broad Epigenetics Collaboration with Buyout Option
-
Shire Licenses Sangamo’s Genome-Editing Technology for Haemophilia and Other Monogenic Diseases
RSS